Eli Lilly and Co solidified its lead in the obesity drug market after trial data for retatrutide showed the highest weight loss prospects to date. The company's shares rose 1.6% on Monday following the American Diabetes Association conference in the United States. This performance sets a high bar for rivals attempting to enter a sector currently dominated by Eli Lilly and Co and Novo Nordisk A/S.
Eli Lilly Stays Ahead in Competitive Obesity Drug Market
Eli Lilly shares rose after trial data for retatrutide showed potential for industry-leading weight loss. While competitors like Roche and AstraZeneca presented new data at a major conference, analysts suggest Lilly remains the frontrunner in efficacy and market segmentation.
Xurve View
洞察:
Xurve View
RBC analyst Trung Huynh said Eli Lilly and Co next-generation products outpace current offerings from competitors in terms of weight loss and side effects. While Eli Lilly and Co gained, shares of Novo Nordisk A/S fell 4.2% on Monday. Roche Holding AG, Pfizer Inc, and Zealand Pharma A/S also saw share prices decline.











